%0 Journal Article
%T Methionine and vitamin B©\complex ameliorate antitubercular drugs©\induced toxicity in exposed patients
%A Abidemi J. Akindele
%A Kennedy I. Amagon
%A Olufunsho Awodele
%J Archive of "Pharmacology Research & Perspectives".
%D 2017
%R 10.1002/prp2.360
%X Tuberculosis therapy utilizes drugs that while effective cause treatment©\related toxicity. Modulation of antitubercular drugs©\induced toxicity by methionine and vitamin B©\complex in patients was evaluated. 285 treatment©\na£¿ve tuberculosis patients at the Chest Clinics of Infectious Diseases Hospital, Yaba and General Hospital, Lagos in Lagos, Nigeria was prospectively recruited and allotted into test (antitubercular medicines, methionine and vitamin B©\complex) and control groups (antitubercular medicines). Data on adverse drug reactions and blood samples were collected at initiation, 2 months and 6 months, and then analyzed. Red blood cells and packed cell volume were significantly higher (P < 0.05) in the test group compared to control at 6 months of therapy. At the end of 2 months, results showed a significant decrease (P < 0.001) in aspartate aminotransferase, alkaline phosphatase, alanine aminotransferase, urea, creatinine and total bilirubin in the test group compared to control. Reduced glutathione and superoxide dismutase were significantly increased (P < 0.001) and malondialdehyde significantly decreased (P < 0.001) in the test versus control groups at the end of 2 and 6 months. Adverse drug reactions were significantly lower (P < 0.001) in the test group (32.4%) compared to control group (56.2%), with 1 death. Hepatotoxicity was significantly higher (P = 0.026) in control (6.9%), compared to test group (0%). Alcohol and cigarette smoking were significantly (P = 0.019 and P = 0.027) associated with the occurrence of adverse drug reactions. Methionine and vitamin B©\complex modulated hepatic, renal, hematological, antioxidant indices and adverse effects in patients administered antitubercular medicines. Such interventions can enhance compliance and better treatment outcomes in tuberculosis patients
%K Antioxidants
%K biomarkers
%K drug toxicity
%K methionine
%K modulation
%K tuberculosis
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5625164/